Any feedback?
Literature summary for 2.3.1.43 extracted from
- Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I (2008), Diabetologia, 51, 1008-1017.
Activating Compound
| Activating Compound | Comment | Organism | Structure |
|---|---|---|---|
| apolipoprotein A-I | the impact of glycation on apolipoprotein A-I structure and its ability to activate LCAT is investigated: The rate of LCAT-mediated cholesterol esterification in reconstituted HDL containing phosphatidylcholine and apoA-I varied according to the level of apoA-I glycation and progressively decreases as the extent of apoA-I glycation increases | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| blood plasma | - |
Homo sapiens | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| phosphatidylcholine + cholesterol | - |
Homo sapiens | 1-acylglycerophosphocholine + cholesteryl ester | - |
? |  |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| LCAT | - |
Homo sapiens |
| lecithin-cholesterol acyltransferase | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
